Please login to the form below
Pfizer scraps RA drug
Pfizer has decided to scrap development of TRU-015 for the treatment of rheumatoid arthritis
Pfizer has decided to scrap development of a drug for a very large market – rheumatoid arthritis (RA). Seattle-based Trubion Pharmaceuticals, which has a collaboration in RA with the company, said that Pfizer has terminated development of TRU-015, a protein therapeutic product.
The decision is based on a phase IIb study which did not meet its primary endpoint of a 20 per cent reduction on an American College of Rheumatology disease scoring index compared to placebo.
Trubion noted that Pfizer intends to continue development of another RA product that is part of the collaboration, SBI-087. That drug is currently in a phase II study.
Share
Related Hub content
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- AstraZeneca announces major expansion of Canadian research footprint
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
